A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Trial Profile

A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Barasertib (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 03 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 03 Oct 2011 Actual initiation date (Sep 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top